206 related articles for article (PubMed ID: 36248860)
1. Single-cell sequencing reveals effects of chemotherapy on the immune landscape and TCR/BCR clonal expansion in a relapsed ovarian cancer patient.
Ren Y; Li R; Feng H; Xie J; Gao L; Chu S; Li Y; Meng F; Ning Y
Front Immunol; 2022; 13():985187. PubMed ID: 36248860
[TBL] [Abstract][Full Text] [Related]
2. Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.
James NE; Woodman M; De La Cruz P; Eurich K; Ozsoy MA; Schorl C; Hanley LC; Ribeiro JR
Front Immunol; 2022; 13():965331. PubMed ID: 36131935
[TBL] [Abstract][Full Text] [Related]
3. Altered tumor signature and T-cell profile after chemotherapy reveal new therapeutic opportunities in high-grade serous ovarian carcinoma.
Kang H; Hwang S; Kang H; Jo A; Lee JM; Choi JK; An HJ; Lee HO
Cancer Sci; 2024 Mar; 115(3):989-1000. PubMed ID: 38226451
[TBL] [Abstract][Full Text] [Related]
4. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis.
Yang B; Li X; Zhang W; Fan J; Zhou Y; Li W; Yin J; Yang X; Guo E; Li X; Fu Y; Liu S; Hu D; Qin X; Dou Y; Xiao R; Lu F; Wang Z; Qin T; Wang W; Zhang Q; Li S; Ma D; Mills GB; Chen G; Sun C
Cell Rep Med; 2022 Dec; 3(12):100856. PubMed ID: 36543113
[TBL] [Abstract][Full Text] [Related]
5. Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer.
Yoshida-Court K; Karpinets TV; Mitra A; Solley TN; Dorta-Estremera S; Sims TT; Delgado Medrano AY; El Alam MB; Ahmed-Kaddar M; Lynn EJ; Sastry KJ; Zhang J; Futreal A; Nick A; Lu K; Colbert LE; Klopp AH
PLoS One; 2023; 18(1):e0279590. PubMed ID: 36607962
[TBL] [Abstract][Full Text] [Related]
6. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
[TBL] [Abstract][Full Text] [Related]
7. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
8. T-Cell Receptor Repertoire Characteristics Associated with Prognostic Significance in High-Grade Serous Ovarian Carcinoma.
Kim JW; Kim S; Yang SY; Joung JG; Hwang S
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107543
[TBL] [Abstract][Full Text] [Related]
9. Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer.
Adzibolosu N; Alvero AB; Ali-Fehmi R; Gogoi R; Corey L; Tedja R; Chehade H; Gogoi V; Morris R; Anderson M; Vitko J; Lam C; Craig DB; Draghici S; Rutherford T; Mor G
Front Immunol; 2023; 14():1204148. PubMed ID: 37435088
[TBL] [Abstract][Full Text] [Related]
10. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
11. Association between effector-type regulatory T cells and immune checkpoint expression on CD8
Sato S; Matsushita H; Shintani D; Kobayashi Y; Fujieda N; Yabuno A; Nishikawa T; Fujiwara K; Kakimi K; Hasegawa K
BMC Cancer; 2022 Apr; 22(1):437. PubMed ID: 35449092
[TBL] [Abstract][Full Text] [Related]
12. scRNA+TCR+BCR-seq revealed the proportions and gene expression patterns of dual receptor T and B lymphocytes in NPC and NLH.
Yao Y; Wang H; Xu Y; Zhang L; Liu R
Biochem Biophys Res Commun; 2024 May; 709():149820. PubMed ID: 38547605
[TBL] [Abstract][Full Text] [Related]
13. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.
Webb JR; Wick DA; Nielsen JS; Tran E; Milne K; McMurtrie E; Nelson BH
Gynecol Oncol; 2010 Sep; 118(3):228-36. PubMed ID: 20541243
[TBL] [Abstract][Full Text] [Related]
14. Revealing Clonal Responses of Tumor-Reactive T-Cells Through T Cell Receptor Repertoire Analysis.
Aoki H; Shichino S; Matsushima K; Ueha S
Front Immunol; 2022; 13():807696. PubMed ID: 35154125
[TBL] [Abstract][Full Text] [Related]
15. Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma.
Xu AM; Haro M; Walts AE; Hu Y; John J; Karlan BY; Merchant A; Orsulic S
Sci Adv; 2024 Apr; 10(16):eadk8805. PubMed ID: 38630822
[TBL] [Abstract][Full Text] [Related]
16. Characterization of ascites- and tumor-infiltrating γδ T cells reveals distinct repertoires and a beneficial role in ovarian cancer.
Foord E; Arruda LCM; Gaballa A; Klynning C; Uhlin M
Sci Transl Med; 2021 Jan; 13(577):. PubMed ID: 33472952
[TBL] [Abstract][Full Text] [Related]
17. Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer.
Zhang J; He T; Yin Z; Shang C; Xue L; Guo H
Front Oncol; 2022; 12():864021. PubMed ID: 35875098
[TBL] [Abstract][Full Text] [Related]
18. Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing.
Jang M; Yew PY; Hasegawa K; Ikeda Y; Fujiwara K; Fleming GF; Nakamura Y; Park JH
Oncoimmunology; 2015 Nov; 4(11):e1030561. PubMed ID: 26451311
[TBL] [Abstract][Full Text] [Related]
19. A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma.
Sun CY; Su TF; Li N; Zhou B; Guo ES; Yang ZY; Liao J; Ding D; Xu Q; Lu H; Meng L; Wang SX; Zhou JF; Xing H; Weng DH; Ma D; Chen G
Oncotarget; 2016 Jan; 7(3):3245-54. PubMed ID: 26675546
[TBL] [Abstract][Full Text] [Related]
20. Immune Tumor Microenvironment in Ovarian Cancer Ascites.
Almeida-Nunes DL; Mendes-Frias A; Silvestre R; Dinis-Oliveira RJ; Ricardo S
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
